You can buy or sell Novan and other stocks, options, ETFs, and crypto commission-free!
Novan, Inc. Common Stock, also called Novan, is a biotechnology company, which engages in leveraging nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Read More Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.
Morrisville, North Carolina
52 Week High
52 Week Low
Yahoo FinanceMay 7
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the treatment of atopic dermatitis and Phase 2 trial with SB206 gel for the treatment of molluscum contagiosum will be presented at the 77th Annual Meeting of the Annual Meeting of the Society for Investigative Dermatology. The meeting will be held May 8-11, 2019 in Chicago, Illinois. Clinical and biomarker results from t...
Yahoo FinanceMay 6
Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.
SAN DIEGO--(BUSINESS WIRE)-- Phase 3 drug candidate targeting molluscum Ligand Pharmaceuticals Incorporated (LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum. Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 million in regulatory and commercial milestones. Novan is responsible for all exp...
Yahoo FinanceMay 1
Novan Confirms Corporate Update Conference Call and Webcast
MORRISVILLE, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019 at 8:15 am Eastern Time to provide an update on the Company’s recent financing, clinical development plan and business model. A moderated question and answer session will be available after the update. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to particip...
-$0.27 per share
Expected May 28, Pre-Market